Additionally, CMTM6 is a critical regulator of PD-L1 stability in a broad range of cancer cells, and dual inhibition of HER2 and PD-L1 successfully enhances the anti-tumor effect of anti-HER2 monotherapy in HER2-positive tumor cell [65]. Here, ERBB2 is linked to neoplasm.